金振口服液治疗儿童COVID-19的随机对照非劣效多中心试验
该随机对照开放标签多中心非劣效试验纳入240例轻中度COVID-19住院儿童,1:1分为金振口服液组117例和金花清感颗粒阳性对照组123例,治疗14天并随访14天。金振组首次病毒检测转阴时间中位6.0天(95%CI 5.0-6.0),短于对照组中位7.0天(95%CI 7.0-8.0);主要症状消失时间与率与对照组相当,咽痛消失时间和住院时间显著缩短;金振组不良事件0.0%,对照组0.8%,均无严重不良事件。结论认为金振口服液治疗儿童轻中度COVID-19安全有效,在缩短转阴时间等方面非劣于金花清感颗粒。
要点
- 金振口服液组首次病毒检测转阴时间中位6.0天,短于金花清感颗粒组7.0天。
- 两组主要症状消失时间与率相当,金振组咽痛消失时间和住院时间显著缩短。
- 金振组不良事件0.0%,对照组0.8%,均无严重不良事件。
核心结论
- 金振口服液治疗儿童轻中度COVID-19安全有效,在缩短首次病毒检测转阴时间、主要症状消失时间与率及住院时间方面非劣于金花清感颗粒。
- 结果提示金振口服液可作为儿童COVID-19患者的推荐治疗药物。
研究设计与样本
- 随机对照、开放标签、多中心、非劣效临床研究,纳入轻中度COVID-19住院儿童。
- 共240例患儿按1:1随机分为金振口服液组117例和金花清感颗粒阳性对照组123例。
- 两组分别接受相应药物治疗14天,停药后随访14天。
主要发现
- 金振组首次病毒检测转阴时间中位6.0天(95%CI 5.0-6.0),显著短于对照组中位7.0天(95%CI 7.0-8.0)。
- 主要临床症状消失时间与率与阳性对照组相当。
- 金振组咽痛消失时间和住院时间显著缩短。
- 两组均无治疗后加重至重型或危重型的参与者。
- 金振组不良事件发生率0.0%,对照组0.8%,两组均无严重不良事件。
关键数值与推荐
- 主要疗效终点为首次病毒检测转阴时间。
- 次要终点包括主要症状消失时间与率、住院时间、症状由无症状或轻转为中或重/危重比例。
- 安全性终点为任何不良事件。
临床怎么用
- 对轻中度COVID-19住院儿童,可考虑使用金振口服液治疗14天。
- 金振口服液在缩短转阴时间和住院时间方面不劣于金花清感颗粒。
局限性
- 研究为开放标签设计,未设盲法。
- 随访时间为停药后14天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: As the coronavirus disease 2019 (COVID-19) pandemic progressed, especially with the emergence of the Omicron variant, the proportion of infected children and adolescents increased significantly. Some treatment such as Chinese herbal medicine has been administered for COVID-19 as a therapeutic option. Jin-Zhen Oral Liquid is widely used for pediatric acute bronchitis, while the efficacy and safety in the treatment of pediatric COVID-19 are unclear. Methods: We conducted a randomized controlled, open-label, multicenter, non-inferiority clinical study involving hospitalized children with mild to moderate COVID-19. Children eligible for enrollment were randomly assigned in a 1:1 ratio to Jin-Zhen Oral Liquid (the treatment group) and Jinhua Qinggan Granules (the positive control group) and received the respective agent for 14 days, followed by a 14-day follow-up after discontinuation of the treatment. The primary efficacy endpoint was the time to first negative viral testing. The secondary endpoints were the time and rate of major symptoms disappearance, duration of hospitalization, and the proportion of symptoms changed from asymptomatic or mild to moderate or severe/critical illness. In addition, the safety end points of any adverse events were observed. Results: A total of 240 child patients were assigned randomly into the Jin-Zhen Oral Liquid (117 patients) and Jinhua Qinggan Granules (123 patients) groups. There was no significant difference of the baselines in terms of the clinical characteristics and initial symptoms between the two groups. After 14-day administration, the time to first negative viral testing in the Jin-Zhen group (median 6.0 days, 95% CI 5.0-6.0) was significantly shorter compared with the positive control Jinhua Qinggan Granules group (median 7.0 days, 95% CI 7.0-8.0). The time and rate of major clinical symptoms disappearance were comparable to the positive control. The symptom disappearance time of pharyngalgia and hospitalization duration were significantly shortened in the Jin-zhen Oral Liquid group. No participants in either group experienced post-treatment exacerbation to severe or critical illness. No adverse events were observed in the Jin-Zhen Oral Liquid treatment group (0.0%) while 1 patient with adverse events occurred in the positive control Jinhua Qinggan granules group (0.8%). No serious adverse events were observed during the study period in both groups. Conclusion: Jin-Zhen Oral Liquid is safe and effective in the treatment of mild to medium COVID-19 in children. It is non-inferior to Jinhua Qinggan granules in shortening the time to first negative viral testing, the time and rate of major clinical symptoms disappearance, and the hospitalization duration. The results suggest that Jin-Zhen Oral Liquid can be a recommended drug for treatment of pediatric COVID-19 patients.
引用
- Dong Q, Qiao H, Jiang H, et al. Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers. Front Pharmacol. 2023. PMID: 36923353. doi:10.3389/fphar.2023.1094089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。